Board of Directors

Mathias Uhlén, Ph.D.

Chairman
Dr Uhlén is co-founder of Atlas Antibodies AB, and Professor of Biotechnology at the Royal Institute of Technology in Stockholm. Dr Uhlén is Program Director of the Human Protein Atlas program. Dr Uhlén is member of the Board of Directors of Biotage AB (publ), Skanditek AB (publ), Nordiag ASA (publ), Novozymes A/S (publ), Affibody AB, KTH Holding AB and SweTree Genomics AB.

Marianne Hansson, Ph.D.

Chief Executive Officer
Dr Hansson is co-founder of Atlas Antibodies AB. Dr Hansson has a research background in biotechnology and more than 8 years experience in marketing and business development, most recently from Affibody AB. Dr Hansson earned her PhD from the Royal Institute of Technology.

Hans Andreasson

Board member
Mr Andreasson is a partner with Scandinavian Life Science Venture. Mr Andreasson has twenty years experience from the diagnostics and biotech tools business. He has an MSc from Chalmers and an MBA from INSEAD. He is a board member of AdvanDx Inc and Oncolog Medical AB.

Torben Jørgensen

Board member
Mr Jørgensen is CEO and President of Biotage AB. Mr Jørgensen has more than 10 years of experience from sales and marketing of antibody research reagents and diagnostic products as CEO of the Danish company Dako AS between 1989 and 1999. Mr Jørgensen was CEO of Karo Bio 2000 to 2001 and CEO of Affibody AB from 2001 to 2005. Mr Jørgensen is member of the Board of Directors of MIP Technologies.

Jakob Lindberg

Board member
Mr Lindberg is Vice President at Investor Growth Capital. Mr Lindberg is a member of the Board of Directors of Cellectricon AB, Scibase AB, Sidec AB, Swedish Orphan International AB and Åmic AB.

Fredrik Pontén, M.D., Ph.D.

Board member
Dr Pontén is co-founder of Atlas Antibodies AB, and Professor and board-certified specialist of pathology at the Uppsala University Hospital. Dr Pontén is Vice Program Director for the Human Protein Atlas program and responsible for the Uppsala site.

Mikael Mortensen

Deputy
Mr. Mortensen is CFO and partner at Scandinavian Life Science Venture. Prior to joining SLS Venture in 2004, Mr. Mortensen was CFO at Melacure Therapeutics AB, between 2001 and 2004, and before that Mr. Mortensen held the position as acting Group Controller and Financial Manager at SchlumbergerSema (acquired by WM-data). Between 1989 and 2000, Mortensen held various CFO positions at ETOUR, County Administration of Jämtland, Swedish National Board of Student Aid (CSN) and Riksbyggen AB.

Karl Swartling

Deputy
Mr Swartling is a Managing Director at Investor Growth Capital. Mr Swartling is member of the Board of Directors of Aerocrine AB, Affibody AB, Cambio Healthcare Systems, Cellectricon AB, Doxa AB, Neuronova AB, AB Mando and Sörman Information och Media.